Pathogen Dynamics Across Clinical Syndromes: A Four-Year Institutional Surveillance of Healthcare-Associated Infections in Ecuador

Henry J. Parra-Vera; Dayci C. Buele-Chica; Galo G. Farfán-Cano; Maria Solorzano-Bravo

doi:10.54034/mic.e2723

Authors

Henry J. Parra-Vera Microbiological Research Centre (CIM), Guayaquil, Ecuador.
Dayci C. Buele-Chica Microbiology Research Centre (CIM). Guayaquil, Ecuador
Galo G. Farfán-Cano FarCan, SilRoj, et al. Medicine and Research Group. Guayaquil, Ecuador
Maria Solorzano-Bravo King Juan Carlos University, Spain

DOI:

https://doi.org/10.54034/mic.e2723

Keywords:

Cross Infection, Drug Resistance, Microbial, Acinetobacter baumannii, Klebsiella pneumoniae, Escherichia coli, Pseudomonas aeruginosa, Staphylococcus aureus, Candida albicans

Abstract

Introduction: Local institutional microbiological profiles are relevant for empirical therapy, infection-prevention planning, and antimicrobial stewardship, particularly in resource-limited settings where standardized surveillance data remain limited. Materials and Methods: A retrospective descriptive surveillance analysis was conducted using aggregated microbiological data from institutional healthcare-associated infection (HAI) surveillance between January 2022 and July 2025 in a secondary-level hospital in Ecuador. Reported HAIs were categorized as ventilator-associated pneumonia (VAP), bloodstream infection (BSI), urinary tract infection (UTI), and surgical site infection (SSI). Prioritized pathogens included Acinetobacter baumannii, Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, Staphylococcus aureus, and Candida albicans. Absolute frequencies and relative proportions were analyzed descriptively. Results: A total of 1,013 reported HAIs were identified. VAP was the most frequent syndrome (331 cases; 32.7%), followed by BSI (219; 21.6%), UTI (64; 6.3%), and SSI (24; 2.4%). Among prioritized pathogens, Acinetobacter baumannii was the most frequently reported microorganism (127 isolates; 12.5% of total HAIs). Pseudomonas aeruginosa was recorded from 2023 onward and showed the highest number of reports in 2024, while Klebsiella pneumoniae was more frequently reported during 2024 and January-July 2025. Escherichia coli remained mainly associated with urinary isolates. Staphylococcus aureus was infrequent overall but was more frequently reported during January-July 2025. Candida albicans was recorded only in 2022 within the prioritized surveillance dataset. Conclusion: Reported HAIs in this institution were predominantly represented by VAP and BSI, with a prioritized microbiological profile dominated by non-fermenting Gram-negative bacilli, particularly A. baumannii. These findings should be interpreted as descriptive institutional surveillance signals rather than definitive incidence trends, because standardized denominators, patient-level variables, antimicrobial susceptibility trends, and isolate deduplication were unavailable. The results support strengthening standardized microbiological surveillance, device-associated infection monitoring, and future integration of antimicrobial resistance data.

References

1. Abarca-Coloma L, Puga-Tejada M, Nuñez-Quezada T, et al. Risk factors associated with mortality in Acinetobacter baumannii infections: results of a prospective cohort study in a tertiary public hospital in Guayaquil, Ecuador. Antibiotics (Basel). 2024;13:213. doi:10.3390/antibiotics13030213.

2. Carrillo JV, Ávila O, Campozano V, et al. Correlación entre microorganismos multirresistentes con mortalidad en Unidad de Cuidados Intensivos del Hospital Guasmo Sur, durante el periodo de febrero de 2022 a enero del 2023. Rev Ecuat Cienc Tecnol Innov Salud Publica. 2025;9:21-27. doi:10.31790/inspilip.v9i29.767.

3. Nuñez JMA, Acosta CH. Acinetobacter baumannii: un llamado urgente al personal de salud para fortalecer la prevención de infecciones hospitalarias en Ecuador. Enferm Investiga. 2026;11:1-2. doi:10.31243/ei.uta.v11i1.3180.2026.

4. Sotomayor N, Villacis JE, Burneo N, et al. Carbapenemase genes in clinical and environmental isolates of Acinetobacter spp. from Quito, Ecuador. PeerJ. 2024;12. doi:10.7717/peerj.17199.

5. Alwazzeh MJ, Alnimr A, Al Nassri SA, et al. Microbiological trends and mortality risk factors of central line-associated bloodstream infections in an academic medical center 2015–2020. Antimicrob Resist Infect Control. 2023;12:128. doi:10.1186/s13756-023-01338-5.

6. Calvo M, Stefani S, Migliorisi G. Bacterial infections in intensive care units: epidemiological and microbiological aspects. Antibiotics (Basel). 2024;13:238. doi:10.3390/antibiotics13030238.

7. Mirhoseini SH, Nikaeen M, Shamsizadeh Z, et al. Hospital air: a potential route for transmission of infections caused by β-lactam-resistant bacteria. Am J Infect Control. 2016;44:898-904. doi:10.1016/j.ajic.2016.01.041.

8. Hayakawa K, Binh NG, Co DX, et al. Clinical and microbiological evaluation of ventilator-associated pneumonia in an intensive care unit in Vietnam. Infect Prev Pract. 2023;5:100318. doi:10.1016/j.infpip.2023.100318.

9. Sandu AM, Chifiriuc MC, Vrancianu CO, et al. Healthcare-associated infections: the role of microbial and environmental factors in infection control—a narrative review. Infect Dis Ther. 2025;14:933-971. doi:10.1007/s40121-025-01143-0.

10. Sandu AM, Vrancianu CO, Tantu AC, et al. Epidemiology of healthcare-associated infections caused by multidrug-resistant bacteria and antimicrobial resistance patterns in a Romanian tertiary care hospital. J Clin Med. 2026;15:667. doi:10.3390/jcm15020667.

11. Haque S, Ahmed A, Islam N, et al. High prevalence of multidrug-resistant bacteria in the trachea of intensive care units admitted patients: evidence from a Bangladeshi hospital. Antibiotics (Basel). 2024;13:62. doi:10.3390/antibiotics13010062.

12. AbdelHalim MM, El Sherbini SA, Ahmed ESS, et al. Management of ventilator-associated pneumonia caused by Pseudomonas and Acinetobacter organisms in a pediatric center: a randomized controlled study. Medicina (Kaunas). 2024;60:2098. doi:10.3390/medicina60122098.

13. Sharma UK, Shah AD. Antimicrobial resistance patterns and clinical outcomes in ventilator-associated pneumonia. Bioinformation. 2025;21:2410-2416. doi:10.6026/973206300212410.

14. Rodríguez-Aguirregabiria M. Therapeutic management of health care-associated pneumonia. Rev Esp Quimioter. 2025;38:43-50. doi:10.37201/req/s01.07.2025.

15. Cabanillas Díez-Madroñero C, Raboso Moreno B, Urrutia-Royo B, et al. Nosocomial and ventilator-associated pneumonia. Open Respir Arch. 2025;7:100488. doi:10.1016/j.opresp.2025.100488.

16. Kelkar R, Sangale A, Bhat V, et al. Microbiology of ventilator-associated pneumonia in a tertiary care cancer hospital. Indian J Crit Care Med. 2021;25:421-428. doi:10.5005/jp-journals-10071-23790.

17. Papazian L, Klompas M, Luyt CE. Ventilator-associated pneumonia in adults: a narrative review. Intensive Care Med. 2020;46:888-906. doi:10.1007/s00134-020-05980-0.

18. Miron M, Ristescu A, Blaj M, et al. Clinical and microbiological profile of hospital-acquired and ventilator-associated pneumonia in critically ill patients: a retrospective observational study. Antibiotics (Basel). 2026;15:232. doi:10.3390/antibiotics15020232.

19. Rosenthal VD, Jin Z, Valderrama-Beltran SL, et al. Multinational prospective cohort study over 24 years of the risk factors for ventilator-associated pneumonia in 187 ICUs in 12 Latin American countries: findings of INICC. J Crit Care. 2023;74:154246. doi:10.1016/j.jcrc.2022.154246.

20. Bayrakçi S, Şahin A, Bayrakçi O, et al. Characteristics of ventilator-associated pneumonia due to Gram-negative bacteria in the intensive care unit: a single-center experience. Medicine (Baltimore). 2025;104. doi:10.1097/MD.0000000000042946.

21. Sharma J, Mohanty S. Ventilator-associated pneumonia: a persistent menace in the ICU. Indian J Crit Care Med. 2025;29:285-286. doi:10.5005/jp-journals-10071-24945.

22. Vasco G, Achig M, Prado-Vivar B, et al. Endogenous origin of Pseudomonas aeruginosa infecting hospitalized patients in Ecuador. Infect Prev Pract. 2023 Dec 11;6(1):100331. doi: 10.1016/j.infpip.2023.100331.

23. Vasco G, Trueba G. Pseudomonas aeruginosa transition from environmental generalist to human pathogen. Av Cienc Ing (Quito). 2021;13:11. doi:10.18272/aci.v13i1.2225.

24. Pazmay Espinoza PA, Quintero Montaño HP. Perfil de resistencia de Pseudomonas aeruginosa por infección nosocomial en pacientes atendidos en el Hospital de Infectología Guayaquil 2020–2023. Polo Conoc. 2025;10(5):703-754. doi:10.23857/pc.v10i5.9473.

25. Biswas S, Baig MMA, Amiry AA, et al. Microbiological landscape in critical care: 14-year analysis of 42,722 ICU patients using MIMIC-IV database. Int J Infect Dis. 2026;166:108501. doi:10.1016/j.ijid.2026.108501.

26. Duhaniuc A, Sima CM, Buruiană G, et al. Antibiotic resistance patterns of bacteria involved in colonization and/or infection of patients in intensive care units in Northeastern Romania. Antibiotics (Basel). 2025;14:1063. doi:10.3390/antibiotics14111063.